Stock Track | Junshi Bio Soars 5.01% Intraday on Anticipation of AACR Clinical Data for JS207 and JS212

Stock Track

04/17

Junshi Bio's stock (01877) soared 5.01% during intraday trading on Friday, reflecting significant investor interest.

The surge appears driven by expectations surrounding the company's upcoming presentations at the American Association for Cancer Research (AACR) 2026 Annual Meeting. According to analyst notes, Junshi Bio is scheduled to disclose clinical data for JS207 (PD-1/VEGF) in first-line colorectal cancer and hepatocellular carcinoma, with potential entry into key registration trials this year. Additionally, early-stage data for JS212 (EGFR/HER3 ADC) will be presented, with pivotal registration trials planned to start by year-end.

Investors are positioning ahead of the data releases, betting on positive outcomes that could accelerate the drug candidates' development pathways and enhance the company's oncology portfolio value.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1197879920"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1197879920\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1197879920?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-17 13:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197879920","market":"sg","top_or_hot":-1,"title":"Stock Track | Junshi Bio Soars 5.01% Intraday on Anticipation of AACR Clinical Data for JS207 and JS212","media":"Stock Track","content":"<p>Junshi Bio's stock (01877) soared 5.01% during intraday trading on Friday, reflecting significant investor interest.</p><p>The surge appears driven by expectations surrounding the company's upcoming presentations at the American Association for Cancer Research (AACR) 2026 Annual Meeting. According to analyst notes, Junshi Bio is scheduled to disclose clinical data for JS207 (PD-1/VEGF) in first-line colorectal cancer and hepatocellular carcinoma, with potential entry into key registration trials this year. Additionally, early-stage data for JS212 (EGFR/HER3 ADC) will be presented, with pivotal registration trials planned to start by year-end.</p><p>Investors are positioning ahead of the data releases, betting on positive outcomes that could accelerate the drug candidates' development pathways and enhance the company's oncology portfolio value.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Junshi Bio Soars 5.01% Intraday on Anticipation of AACR Clinical Data for JS207 and JS212</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Junshi Bio Soars 5.01% Intraday on Anticipation of AACR Clinical Data for JS207 and JS212\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-17 13:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Junshi Bio's stock (01877) soared 5.01% during intraday trading on Friday, reflecting significant investor interest.</p><p>The surge appears driven by expectations surrounding the company's upcoming presentations at the American Association for Cancer Research (AACR) 2026 Annual Meeting. According to analyst notes, Junshi Bio is scheduled to disclose clinical data for JS207 (PD-1/VEGF) in first-line colorectal cancer and hepatocellular carcinoma, with potential entry into key registration trials this year. Additionally, early-stage data for JS212 (EGFR/HER3 ADC) will be presented, with pivotal registration trials planned to start by year-end.</p><p>Investors are positioning ahead of the data releases, betting on positive outcomes that could accelerate the drug candidates' development pathways and enhance the company's oncology portfolio value.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01877","symbol_name":"君实生物","start_time":0,"source_url":"","article_id":"1197879920","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197879920","pubTimestamp":1776404469,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Junshi Bio's stock (01877) soared 5.01% during intraday trading on Friday, reflecting significant investor interest.The surge appears driven by expectations surrounding the company's upcoming...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01877":"君实生物"},"translate_title":"个股赛道|君实生物盘中暴涨5.01%，JS207、JS212获AACR临床数据预期","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01877":1},"content_text":"Junshi Bio's stock (01877) soared 5.01% during intraday trading on Friday, reflecting significant investor interest.The surge appears driven by expectations surrounding the company's upcoming presentations at the American Association for Cancer Research (AACR) 2026 Annual Meeting. According to analyst notes, Junshi Bio is scheduled to disclose clinical data for JS207 (PD-1/VEGF) in first-line colorectal cancer and hepatocellular carcinoma, with potential entry into key registration trials this year. Additionally, early-stage data for JS212 (EGFR/HER3 ADC) will be presented, with pivotal registration trials planned to start by year-end.Investors are positioning ahead of the data releases, betting on positive outcomes that could accelerate the drug candidates' development pathways and enhance the company's oncology portfolio value.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}